Insights

Innovative Therapeutic Focus Piton Therapeutics specializes in developing first-in-class drugs targeting unmet needs in chronic conditions such as IBD, autism, and Parkinson’s disease, offering opportunities to collaborate on pioneering treatments addressing large patient populations.

Growing Clinical Pipeline With plans to initiate in-human trials for ulcerative colitis in 2025 and ongoing development for autism spectrum disorder, Piton presents potential for early-stage partnership or licensing opportunities in cutting-edge therapies.

Strategic Platform Advantage Utilizing an AI-driven proprietary platform focused on the gut microbiome enables Piton to rapidly identify promising drug candidates, positioning them as a potential partner for companies seeking innovative microbiome-based solutions.

Market Expansion Potential Research suggesting applications of Piton’s UC therapy in type 2 diabetes and weight management indicates substantial market expansion opportunities across metabolic and obesity markets, ideal for broadening therapeutic collaborations.

Strong IP & Expertise With a robust intellectual property portfolio and a talented advisory team, Piton is well-positioned to scale strategic partnerships, licensing deals, or joint ventures that leverage their novel platform and targeted therapeutics.

Similar companies to Piton Therapeutics, Inc.

Piton Therapeutics, Inc. Tech Stack

Piton Therapeutics, Inc. uses 8 technology products and services including jsDelivr, Open Graph, Squarespace, and more. Explore Piton Therapeutics, Inc.'s tech stack below.

  • jsDelivr
    Content Delivery Network
  • Open Graph
    Content Management System
  • Squarespace
    Content Management System
  • Cart Functionality
    E-commerce
  • Stimulus
    Javascript Frameworks
  • Choices
    Javascript Libraries
  • Priority Hints
    Performance
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

Piton Therapeutics, Inc.'s Email Address Formats

Piton Therapeutics, Inc. uses at least 2 format(s):
Piton Therapeutics, Inc. Email FormatsExamplePercentage
First.Last@precidiag.comJohn.Doe@precidiag.com
71%
First@precidiag.comJohn@precidiag.com
17%
FL@precidiag.comJD@precidiag.com
6%
First.Last@precidiag.comJohn.Doe@precidiag.com
6%
First@pitontx.comJohn@pitontx.com
100%

Frequently Asked Questions

What is Piton Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc.'s official website is pitontx.com and has social profiles on LinkedIn.

What is Piton Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Piton Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Piton Therapeutics, Inc. has approximately 16 employees across 1 continents, including North America. Key team members include Chief Executive Officer: N. M.President & Coo: P. L.Consultant Chief Scientific Officer: P. M.. Explore Piton Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Piton Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Piton Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc.'s tech stack includes jsDelivrOpen GraphSquarespaceCart FunctionalityStimulusChoicesPriority HintsX-Content-Type-Options.

What is Piton Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc.'s email format typically follows the pattern of First.Last@precidiag.com. Find more Piton Therapeutics, Inc. email formats with LeadIQ.

When was Piton Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Piton Therapeutics, Inc. was founded in 2016.

Piton Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

Piton (“Pee-ton”) is pioneering the development of life-changing, first-in-class therapeutics for chronic conditions with limited therapeutic options. 

The company employs a proprietary platform to discern the gut microbiome’s role in the cause and progression of disease. Therapeutics are developed to precisely target pathogenic pathways in the gut lumen. AI capabilities efficiently identify drug candidates with desired characteristics which are validated in the company’s lab. 

Products consist of small molecule drugs. Piton does NOT develop live bacterial therapeutics (LBTs) or seek to modify the composition of microbiota in the gut.

Piton’s lead pipelines, IBD/Ulcerative Colitis & Autism Spectrum Disorder, target unmet needs in markets with 5 million and 50+ million patients, respectively. Parkinson’s Disease constitutes a third area of focus.

Piton's therapeutic approach for Ulcerative Colitis uniquely targets a cause of the disease for a sub-type constituting ~45% of the patient population. The approach has strong support in the clinical community and represents a potential ‘paradigm change’ in the treatment of the disease. In-human trials are anticipated in 2025.

Recently published research suggests that Piton’s therapeutic strategy for UC may have application in the treatment of type 2 diabetes and weight loss management.

Piton’s therapeutic approach for Autism Spectrum Disorder has been validated in successive, in-vivo experiments. Several drug candidates are under consideration for what could be the first approved drug to treat the core symptoms of ASD.

Application of Piton’s discovery platform for Parkinson’s Disease led to the discovery of a causative hypothesis and a target for novel therapeutic intervention. Given strong links between this hypothesis and many chronic diseases, including Intestinal Bowel Disease (IBD), this program may hold cross-disease blockbuster potential.

Piton has strong IP Portfolio & a stellar team of active advisors.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $10M$25M

    Piton Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    Piton Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.